Small Is Beautiful: Insulin-Like Growth Factors and Their Role in Growth, Development, and Cancer
Authors
Discussion
Loading...
Member takes
Implication
Review reveals limited efficacy of insulin-like growth factor receptor inhibitors in advanced cancers, highlighting the need to target cross-resistant signaling pathways.
Key Points
- To review the historical understanding and biological role of insulin-like growth factors in physiology and cancer, while evaluating recent clinical trials targeting the insulin-like growth factor 1 receptor.
- Narrative synthesis examining the regulatory mechanisms of insulin-like growth factors in growth, development, epithelial cancers, and sarcomas.
- Evaluation of recent phase I and phase II clinical trial data evaluating monoclonal antibodies and small molecules directed against the insulin-like growth factor 1 receptor.
- Monoclonal antibody inhibition of the insulin-like growth factor 1 receptor combined with cytotoxic chemotherapy failed to demonstrate clinical efficacy in first-line metastatic non-small-cell lung adenocarcinoma.
- Cross-resistance among related cell signaling networks limits single-agent efficacy, indicating that optimal therapeutic benefit requires co-targeting secondary survival pathways.
Cite This Study
Robert G. Maki (2010) studied this question.